Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) have been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) and Acer Therapeutics (NASDAQ:ACER – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Volatility & Risk Seres Therapeutics has a beta of […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) and Acer Therapeutics (NASDAQ:ACER – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation. Volatility & Risk Seres Therapeutics has a beta of […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) had its target price trimmed by Chardan Capital from $12.00 to $10.00 in a report released on Friday, The Fly reports. Several other brokerages have also issued reports on MCRB. JPMorgan Chase & Co. began coverage on shares of Seres Therapeutics in a report on Friday, April 21st. They […]
Seres Therapeutics (NASDAQ:MCRB – Get Rating) had its price objective reduced by Chardan Capital from $12.00 to $10.00 in a research note released on Friday morning, The Fly reports. A number of other brokerages also recently commented on MCRB. Canaccord Genuity Group lifted their price target on shares of Seres Therapeutics from $11.00 to $15.00 […]